Details of the Drug Reposition

General Information of This Drug (ID: DMC4HT7)

Drug Name
NK100   DMC4HT7
Drug Type
Cell therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Aggressive cancer DISKUCQY 2A00-2F9Z Phase 1 [1]
Acute myelogenous leukaemia DISCSPTN 2A41 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03319459) FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT03081780) Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML). U.S.National Institutes of Health.